Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: A retrospective chart review.
Schizophr Res
December 2024
ClozR Registry and InSTAR Program, Schizophrenia Clinic, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
The response rate to clozapine in patients with treatment-resistant schizophrenia spectrum disorders (TRSS) is around 40 %. But, in general, a better prognosis is noted for schizophrenia in developing countries, including India. Given the scarcity of related literature from India, this study aimed to evaluate the response rates to clozapine in TRSS and explore predictors of response.
View Article and Find Full Text PDFNeuromodulatory techniques in eating disorders: From electroconvulsive therapy to transcranial magnetic stimulation and beyond: A mixed method systematic meta-review.
Psychiatry Res
December 2024
Eating Disorders Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, via Cherasco 15, 10126, Turin, Italy. Electronic address:
Background: Psychosocial and pharmacological interventions can effectively treat eating disorders (EDs), but improvements are often short-term and modest. Neuromodulation, altering nerve activity through targeted neurological stimulation, is an emerging intervention in neuropsychiatric disorders. This meta-review synthesizes evidence on neuromodulatory techniques in ED patients, identifying research gaps and future directions.
View Article and Find Full Text PDFFactors in the development of refractory status epilepticus in status epilepticus patients.
Epilepsy Behav
December 2024
Aksaray University Faculty of Medicine Department of Neurology, Aksaray, Turkiye.
Objectives: Status epilepticus (SE) is a severe neurological condition associated with a poor prognosis. Refractory status epilepticus (RSE) is a treatment-resistant form of SE with an even worse prognosis. The exact mechanisms underlying the development of RSE are not fully understood.
View Article and Find Full Text PDFCAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?
BioDrugs
December 2024
Rheumatology Department, Strasbourg University Hospital, 1 Avenue Molière, 67000, Strasbourg, France.
Chimeric antigen receptor (CAR) T-cell therapy, initially successful in treating hematological malignancies, is emerging as a potential treatment for autoimmune diseases, including rheumatic conditions. CAR T cells, engineered to target and eliminate autoreactive B cells, offer a novel approach to managing diseases like systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myopathies, where B cells play a pivotal role in disease pathology. Early case reports have demonstrated promising results, with patients achieving significant disease remission, normalization of serological markers, and the ability to discontinue traditional immunosuppressive therapies, which supported the initiation of several clinical trials.
View Article and Find Full Text PDFA systematic review of predictors and moderators of treatment response in psychological interventions for persisting forms of depression.
Br J Clin Psychol
December 2024
Clinical and Applied Psychology Unit, School of Psychology, University of Sheffield, Sheffield, UK.
Background: Although psychological interventions can be effective for the treatment of major depressive disorder, some patients' symptoms persist or rapidly recur after therapy. This study aimed to synthesize research findings on predictors and moderators of treatment response for persisting forms of depression, such as chronic, recurrent, and treatment-resistant depression.
Methods: A systematic review of studies investigating predictors and moderators of response to outpatient psychological treatment for adults with persisting forms of depression was conducted by searching Web of Science, Scopus, and PsycInfo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!